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cals and diagnostic (or staging) tests, more than offset by cost savings related to
lower consumption of other health care resources.
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OBJECTIVES: A systematic review of the literature was performed to gather all
official recommendations on the prevention in infants of allergic manifestations
(AM), and, more specifically, atopic dermatitis (AD), by using hydrolyzed infant
formulas (HF) such as partially or extensively hydrolyzed formula (PHF; EHF).
METHODS:OVID MEDLINE® and the grey literature were searched by two reviewers
using the keywords AM, AD, prevention and guidelines. A third person acted as
adjudicator in case of disagreement. Of interest were recommendations pertaining
to the prevention of AM issued by national or regional associations of medical
professionals. RESULTS: This review yielded 11 sets of guidelines published for
Australia, France, Germany, Spain, Switzerland (all n1), Europe and the US (both
n3) between 1999 and 2010. Most guidelines included AD either specifically (n3)
or in the broad context of AMs. Six guidelines (of which 2 recommended PHF over
EHF) endorsed the use of HFs for the prevention of AM in “at risk” infants when
exclusive breastfeeding was not or no longer possible. Two other publications did
not explicitly recommend HFs, but rather formulas with a documented reduced
allergenicity. The need for an appropriate level of nutritional support was stressed
in one publication. Five guidelines acknowledged that not all HFs have the same
protective benefit. . Four publications underlined the importance of sound clinical
evidence when determining the preventive efficacy of HFs. None of the guidelines
based their recommendations on recent evidence from meta-analyses focusing on
a specific brand of PHF NAN-HA®. CONCLUSIONS: HFs and specifically PHFs are
endorsed for the prevention of AMs. The need for a strong validity and universality
of the clinical evidence and methodology is acknowledged by national or regional
medical associations. Hence, recent evidence regarding the preventive efficacy of a
specific brand of PHF, NAN-HA®, should provide the basis for new recommenda-
tions.
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OBJECTIVES: Patch testing is a well-established method to determine whether
contact sensitization to certain agents has occurred and it can directly influence
the clinical outcome of patients with allergic contact dermatitis (ACD) where de-
tection of causative allergens is crucial for appropriate prevention and treatment.
Its positive predictive value, however, is influenced by many variables. In particu-
lar, not all patients referred for patch testing actually have ACD and not all positive
reactions are clinically relevant. The objective of our study was to develop an
outcome indicator of patch testing. METHODS: We identified and measured as a
possible indicator the ratio of patients with allergic and/or photo-allergic contact
dermatitis clinically cured/improved as a result of identification of relevant aller-
gens. Patients with positive reactions considered relevant to their current derma-
titis were interviewed by telephone 2 months after patch/photo-patch testing in
order to assess their clinical outcome in relation to the recommended elimination
of supposedly relevant allergens. We parallely evaluated the prevalence of referral
diagnosis different from ACD in patients whose test results were
negative/non-relevant.RESULTS:Over a 4-year period positive reactions were seen
in 1397 out of 2857 tested patients. Relevance was considered current in 578 sub-
jects, and 506 of them were interviewed. Remission/significant improvement fol-
lowing allergen(s) contact avoidance was reported by 431 patients, the outcome
indicator (431/506) thus scoring 85.2%. Among the 75 patients who reported no
improvement, 41 had not avoided contact with the offending substance(s), 17 had
other persistent concomitant skin conditions, and 17 were unchanged despite
elimination of the alleged relevant allergens. The likely diagnoses of patients
whose test results were negative/non-relevant were: non-eczematous diseases
(39% of total patients), endogenous eczema (22%), irritant contact dermatitis (10%),
unknown (5%), possible ACD from unidentified haptens (4%). CONCLUSIONS: The
ratio of relevantly patch-test-positive patients resolved/improved after allergen
avoidance is a useful patch-testing outcome indicator.
PRS75
HEALTH TECHNOLOGY APPRAISAL OF NEW DRUGS: ARE WE GETTING IT
RIGHT?
Gordon J1, Karnon J2
1University of Adelaide, Adelaide, SA, Australia, 2University of Adelaide, Adelaide, South
Australia, Australia
OBJECTIVES: A particular challenge for economic evaluation of new pharmaceuti-
cals is to address the potential for conflict between 1) the available evidence that
informs decisions about reimbursement coverage, and 2) the reality of how prod-
ucts are used in clinical practice. The aim of this study is to explore the issue of
divergence between actual and evaluated drug pathways and resultant conse-
quences for the appropriateness of technology appraisals and reimbursement cov-
erage decisions. METHODS: We develop a generic decision analytic model to illus-
trate the issue of divergence between actual and evaluated drug pathways arising
from a new product changing the number of lines of therapy available to patients,
rather than displacing existing therapies. Under this generic model, incremental
costs and effects are potentially affected by response to therapy and the clinical
decision to maintain or switch treatment. The potential effects on the estimated
cost-effectiveness of new drugs from the misspecification of the drug pathway are
illustrated using COPD as a case study disease area and prescription utilisation
data from Australia. RESULTS: In the case of treatments for COPD, cost-effective-
ness of new therapies is overestimated when displacement is assumed, but the
real-world utilisation of new products involves additions to reimbursement sched-
ules without displacement and when effect size decreases with therapy line. We
define this as pathway misspecification bias and consider that it may arise in all
disease areas and drug classes. We demonstrate that the size of the bias is posi-
tively related to the proportion of non-responders. CONCLUSIONS: We demon-
strate that without provision to withdraw funding from existing lines of therapy,
cost-effectiveness analysis to inform reimbursement decision-making should be
expanded to include further routine modelling of the likely use of products in
clinical practice. We demonstrate that providing for the withdrawal of funding for
existing technologies may provide for more efficient funding decisions.
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OBJECTIVES: To identify evidence gaps for future economic modelling of Chronic
Obstructive Pulmonary Disease (COPD) by reviewing published Conceptual Models
and studies reporting associations between end-points and disease outcomes.
METHODS: A systematic literature search was undertaken to identify English lan-
guage publications since 2000 in Medline and Embase describing Conceptual Mod-
els of COPD and studies reporting associations between end-points and disease
outcomes. Studies were reviewed against inclusion/exclusion criteria and those
including therapeutic interventions were excluded at screening. RESULTS: Forty-
one published papers were identified: 7 conceptual models of COPD and 34 articles
on associations between endpoints and disease outcomes. Of the 7 conceptual
models, 6 described single aspects of COPD (cognitive function, dyspnoea, brain
function, design of patient related interventions, activity and functional perfor-
mance). Only 1 described a broader set of determinants of health status in COPD
patients (physiological functioning, patient complaints, functional impairment
and quality of life.) 2 review papers on cognitive function and functional perfor-
mance and 1 reporting determinants of functional performance and dyspnoea
based on patient/expert interviews were identified. 31 studies using regression
analyses to estimate associations between relevant parameters in COPD, including
symptoms (mainly dyspnoea), health status, exercise, lung function, exacerba-
tions, quality of life, biomarkers, co-morbidities, mortality and healthcare utiliza-
tion were found. No studies on the use of conceptual models for economic model-
ling in COPD were identified. None of the studies presented a comprehensive set of
determinants of disease progression and outcomes. CONCLUSIONS: It is recom-
mended that models used to support economic evaluations of health care inter-
ventions are based on conceptual models capturing all relevant aspects of the
disease and outcomes of value. The available evidence does not provide a full
spectrum of relationships between diagnosis, disease progression and outcomes
needed for a comprehensive disease based economic model in COPD.
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OBJECTIVES: Applying innovative methods to clinical trial data to identify and
characterize unobserved subgroups of differential responders. METHODS: Data
from three COPD clinical trials was retrospectively analysed using Growth Mixture
Models (GMMs): INHANCE (indacaterol 150g and 300g vs tiotropium 18g and
placebo); INLIGHT-2 (indacaterol 150g vs salmeterol 50g and placebo); and IN-
VOLVE (indacaterol 300g and 600g vs formoterol 12g and placebo). GMMs were
conducted on SGRQ Symptoms Domain data at baseline, 12 weeks, and six months
to identify unobserved subgroups. Baseline characteristics were compared be-
tween emergent subgroups of differential responders in post hoc analyses.
RESULTS:Within INHANCE and INLIGHT-2, two subgroups of patients emerged per
treatment arm: responders (improvement) and non-responders (little change/de-
terioration). Within INOLVE, three subgroups of patients emerged per treatment
arm: responders, non-responders, and partial-responders. When responders were
analysed separately, mean treatment effects in terms of SGRQ Symptom scores
were generally larger than when all patients were included: INHANCE responder
improvements ranged from 8 -12 units compared with 7-14 for all patients;
INLIGHT-2 responder improvements were 3 -13 units versus 3 -8 for all patients;
INVOLVE responder improvements were 5 -17 units vs 3 -11 for all patients. Within
each trial, responders made up the largest proportion of the sample (55% - 82%) but
non-/partial-responder groups were large enough and different enough to dampen
treatment effects when group means were analyzed as a whole. Responders had
significantly better baseline SGRQ Symptom scores than non-responders. Further
significant differences were found between non-responders, partial-responders
and responders in terms of smoking history, age, and breathlessness.
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